Latest Breaking News On - Gossamer bio - Page 5 : comparemela.com

Wedbush Begins Coverage on Gossamer Bio (NASDAQ:GOSS)

Wedbush Begins Coverage on Gossamer Bio (NASDAQ:GOSS)
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

United statesPiper sandlerFaheem hasnainMonashee investment managementGossamer bio incSecurities exchange commissionArmistice capitalSilverarc capital managementVanguard group incVenture managementGoldman sachs groupGossamer bioFree reportMarketbeat ratingsModerate buyGet free report

Merck Drug for Heart and Lung Disorder Wins a First-in-Class FDA Approval

Merck Drug for Heart and Lung Disorder Wins a First-in-Class FDA Approval
medcitynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medcitynews.com Daily Mail and Mail on Sunday newspapers.

Aaron waxmanAcceleron pharmaInstitute for clinicalNew england journalPulmonary heart diseasesEconomic reviewAerovate therapeuticsGossamer bioKeros therapeutics

Attovia Enhances Clinical and Development Expertise with Appointment of Chief Medical Officer and Clinical and Scientific Advisory Boards

Hubert Chen, accomplished drug developer and pharma executive, joins as Chief Medical Officer Industry veterans and leading academic experts .

United statesNew south walesUniversity hospitalNew yorkSalk instituteSan diegoUniversity of pennsylvaniaHaverford collegeSouth walesUniversity of washingtonUnited kingdomHubert chenGenentech rocheDavid kingJonathan silverbergLuisa salter cid

Attovia Enhances Clinical and Development Expertise with Appointment of Chief Medical Officer

Hubert Chen, accomplished drug developer and pharma executive, joins as Chief Medical Officer

United statesHaverford collegeUnited kingdomUniversity of washingtonSan diegoUniversity hospitalNew yorkNew south walesSouth walesSalk instituteUniversity of pennsylvaniaLawrence eichenfieldGenentech rocheTao fuLuisa salter cidHubert chen

Avenzo Therapeutics Announces $150 Million Oversubscribed Financing To Advance Emerging Oncology Pipeline

SAN DIEGO, March 26, 2024 Avenzo Therapeutics announces the closing of an oversubscribed $150 million Series A-1 financing, bringing total capital raised to $347 million.

San diegoUnited statesGenentech rocheJakob dupontAthena countouriotisOncomed pharmaceuticals incEnterprise associatesAvenzo therapeutics incNew enterprise associatesDeep track capitalSofinnova investmentsAvenzo therapeuticsSands capitalDelos capitalExecutive partnerPrivate equity